Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short-term Investments (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Short-term Investments for 12 consecutive years, with $23.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments changed 0.41% to $23.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.7 million, a 0.41% change, with the full-year FY2025 number at $23.7 million, changed 0.41% from a year prior.
  • Short-term Investments was $23.7 million for Q4 2025 at Anika Therapeutics, up from $22.2 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $36.7 million in Q2 2023 to a low of $22.0 million in Q1 2025.
  • A 5-year average of $29.3 million and a median of $29.8 million in 2021 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: soared 1093.24% in 2021, then crashed 31.46% in 2025.
  • Anika Therapeutics' Short-term Investments stood at $29.8 million in 2021, then increased by 16.03% to $34.6 million in 2022, then decreased by 23.87% to $26.4 million in 2023, then dropped by 10.49% to $23.6 million in 2024, then rose by 0.41% to $23.7 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Short-term Investments are $23.7 million (Q4 2025), $22.2 million (Q3 2025), and $24.0 million (Q2 2025).